uniQure N.V.
QURE
Positions held
Your positionsQURE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- uniQure is positioned in the rapidly growing gene therapy sector, which is expected to see significant advancements and increased investment in the coming years.
- Revenue increased by 64% compared to the prior quarter, reaching $5.8 million.
- Gross margin improved to 94%, up from 93.9% in the previous quarter.
- The company's financial health is concerning, with a high debt-to-equity ratio of 170.4, indicating potential risks in managing its liabilities.
- Operating margin remains negative at -764.9%, reflecting ongoing challenges in profitability.
- The overall score indicates a 'Strong Sell' signal with a score of -16.00, suggesting bearish sentiment among analysts.
Fundamentals
| Market cap | $1.56B | Enterprise value | $1.31B | Trailing P/E | — | Forward P/E | -7.45 |
| PEG | — | Price / book | 4.82 | Beta | 1.06 | Dividend yield | 0.00% |
| Revenue growth | 11.0% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -8.7% |
| Profit margin | 0.0% | ROE | -1.6% | ROA | -15.7% | Debt / equity | 1.70 |
| Current ratio | 10.01 | Free cash flow | -$77.58M | Analyst recommendation | strong_buy | Mean target | $62.39 |
| 52w high | $71.50 | 52w low | $8.73 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $5.8M | $3.6M | $5.6M | $3.7M | $5.3M | — |
| Op margin | -764.9% | -1242.8% | -924.8% | -1337.2% | -815.0% | — |
| Net income | -$81.1M | -$53.5M | -$37.1M | -$80.5M | -$37.7M | — |
| Gross margin | 94.0% | 93.9% | 92.2% | 89.2% | 87.5% | — |
| Gross profit | $5.5M | $3.3M | $5.1M | $3.3M | $4.6M | — |
| Operating income | -$44.7M | -$44.3M | -$51.5M | -$49.5M | -$42.9M | — |
- Revenue +64% vs prior quarter ($5.8M vs $3.6M).
- Gross margin 94% (was 93.9% prior quarter).
- Operating margin expanded to -764.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $16.1M | $27.1M | $15.8M | $106M |
| Op margin | -1166.8% | -671.8% | -1783.0% | -135.5% |
| Net income | -$199M | -$240M | -$308M | -$127M |
| Gross margin | 89.5% | 32.4% | 14.0% | 96.9% |
| Gross profit | $14.4M | $8.8M | $2.2M | $103M |
| Operating income | -$188M | -$182M | -$282M | -$144M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s Next
2026-10-05 · UniQure Shares Fall After Barclays Downgrade
2026-10-05 · Barclays Downgrades uniQure to Equal Weight From Overweight
2026-10-02 · RBC Cuts Price Target on uniQure to $48 From $65, Keeps Outperform, Speculative Risk
2026-10-01 · uniQure (QURE) Faces A Fresh AMT 130 Test After Mixed Data, Bargain Or Trap
2026-09-30 · uniQure Plunges on Additional Data From Huntington's Disease Study
2026-09-30 · uniQure Stock Crashed on Its Huntington’s Data. Wall Street’s Price Target Says the Selloff Went Too Far
2026-09-29 · Uniqure Plummets 37% On Another Shocking Twist For Its Huntington's Drug
2026-09-29 · uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit
2026-09-29 · Sector Update: Healthcare Stocks Softer Late Afternoon
2026-09-29 · Update: UniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years; Shares Tumble
Price (daily)
Full chart · RSI · MACD · patterns